TB-500
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
TB-500 is the systemic half of the recovery toolkit — where BPC-157 acts locally and fast, TB-500 is the body-wide “repair coordinator.” It’s a synthetic fragment of thymosin beta-4 (Tβ4), a natural protein your cells use to manage their internal scaffolding (actin) and to orchestrate the cell movement that wound healing depends on. People use it for whole-body recovery, soft-tissue repair, and flexibility, most often paired with BPC-157 in the “Wolverine” stack.
Tβ4 was first isolated in 1981 by Dr. Allan Goldstein at the National Institutes of Health from calf thymus tissue — and it turned out to be one of the most abundant proteins inside human cells, found at elevated concentration wherever the body is actively healing (wound sites, torn tendons, damaged muscle). That observation — Tβ4 piling up at injury sites — is what kicked off four decades of research asking whether the protein causes repair or just shows up because of it. The mechanism work below is what answered that question.
The framing worth keeping: TB-500 is a repair accelerant layered on top of the inputs that actually rebuild tissue — sleep, protein, loading, recovery. On that foundation, the biology is genuinely interesting and the preclinical record is broad. The rest of this article walks the mechanism, what the research shows at each tier (including an honest note on which molecule the human trials used), the protocol people run, and the open questions.
What does it do in my body?
Actin sequestration: the core, best-understood mechanism. Tβ4 grabs free actin monomers (the building blocks of the cell’s internal skeleton) and releases them on demand [PMID 12852258, 17468232]. That control over the cytoskeleton is what lets cells crawl — and migration is the heart of repair: cells have to move into damaged tissue before they can rebuild it. This is also why TB-500 pairs naturally with BPC-157, which drives the local angiogenesis the migrating cells need.
Angiogenesis. Tβ4 promotes new blood vessel formation, increasing perfusion to repairing tissue [PMID 22074294, 27450736].
Anti-inflammatory + anti-fibrotic signaling. Tβ4 down-regulates inflammatory chemokines/cytokines (via NF-κB suppression), reduces TGF-β-driven fibrosis, inhibits the fibroblast-to-myofibroblast conversion that creates scar, and lowers macrophage infiltration [PMID 36580759]. Much of the anti-fibrotic punch may live in a small N-terminal metabolite, ac-SDKP, which has reduced (and in some models reversed) fibrosis in liver, lung, heart, and kidney. This anti-scar-tissue property is part of why TB-500 is emphasized for post-surgical recovery specifically — excess scar formation is a major recovery complication, and TB-500’s profile pushes toward organized repair over fibrosis.
Stem/progenitor activation + cell survival. Tβ4 mobilizes and matures stem/progenitor cells and protects cells from apoptosis [PMID 22074294].
A transparency note on the molecule — and a real labeling trap. Historically “TB-500” meant a shorter synthetic fragment (the active LKKTETQ region) of full Tβ4, and a portion of the active wound-healing biology may reside in specific metabolites. But the term is used inconsistently across vendors: some clinics still use “TB-500” to mean the 7-amino-acid fragment, while higher-tier product (including Alyve’s) is the full 43-amino-acid acetylated thymosin beta-4 sequence — the actual parent molecule the published research is on. Practical takeaway: when you see a study, check whether it used full/recombinant Tβ4 or the fragment — they overlap heavily in mechanism but aren’t identical — and when you buy, confirm which molecule the vial actually contains. That’s a reason to read both the evidence and the COA carefully, not a reason to discount the peptide.
How can it help me?
- Best fit: Systemic recovery support, often stacked with BPC-157 (the “Wolverine” pairing)
- Where the science stands: Deep, mechanistically coherent animal/in-vitro record; human data exists for clinical-grade Tβ4 (eye drops, wound, cardiac)
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
TB-500 is well-tolerated in the available data, with no serious toxicity signal.
- Injection-site reactions (redness, swelling, irritation) — most common; rotate sites, clean technique.
- Mild headache or transient lethargy — occasionally reported.
- No detectable effect in a minority of users — sometimes a product-quality issue (the gray-market fragment’s actual content varies, which is exactly what a COA solves).
- Cancer caution — the same angiogenesis/cell-migration biology that drives repair overlaps mechanistically with tumor biology, so suspected or active malignancy is a sensible contraindication to discuss with an oncologist. This is mechanism-based caution, not documented human harm — and note the anti-fibrotic/anti-inflammatory arms of Tβ4 cut the other way. Pregnancy is also commonly listed as a contraindication.
The largest real-world variable isn’t the side-effect profile — it’s whether the vial contains correctly-dosed, identity-confirmed TB-500 in the first place, which is the supply-chain point below.
Regulatory status: Not FDA-approved for any use. Prohibited by WADA and a well-known doping agent in horse racing (its cytoskeletal/cell-movement effects). The FDA reopened consideration of peptide-compounding policy in 2026, but no approval exists for TB-500. Sold legally as a research chemical, “not for human consumption.” Note that the clinical-grade Tβ4 programs (RGN-259, rhTB4) are separate regulated drug-development efforts and don’t confer approval on the gray-market fragment.
Worth noting the signal value of the equine ban specifically: published methods exist for detecting TB-500 in horse urine and plasma — people watching elite-racehorse injury-recovery timelines (with millions of dollars on the line) decided this molecule warranted a dedicated detection protocol. That’s not proof of human athletic-recovery efficacy, but it is a meaningful inference about what the people closest to high-value soft-tissue injuries believe.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
Reconstitution (objective math). A 10 mg vial reconstituted with 2 mL bacteriostatic water gives 5 mg/mL (5,000 mcg/mL). On a U-100 insulin syringe, a 500 mcg dose = 0.1 mL = 10 units. Add water slowly down the vial wall, swirl gently, never shake; refrigerate reconstituted.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
Two common dosing conventions: and they differ, which is worth knowing:
- Cheat-sheet / clinic convention (one practitioner): 10 mg vial in 2 mL, 500 mcg dosed AM, daily, 8 weeks on / off.
- Forum loading protocol: a loading phase of 2–5 mg twice weekly for the first 4–6 weeks, then a lower-frequency maintenance dose (e.g., 2–5 mg once weekly or every other week). This is a much higher per-injection amount than the cheat-sheet’s daily 500 mcg.
The two reflect different philosophies — daily microgram dosing vs. front-loaded milligram dosing leaning on Tβ4’s longer half-life. Both are in real-world use; the loading-then-maintenance pattern is the more commonly cited approach for TB-500 specifically, because the molecule lasts longer than BPC-157 and doesn’t need daily injections. There’s no human dose-finding trial for the fragment to anchor either, so these are community-converged protocols, stated plainly as such.
Route considerations — why nasal spray is the wrong format for full-length TB-500. ✅ Verified 2026-06-20. Full-length TB-500 (Thymosin Beta-4) is a 43-amino-acid polypeptide with a molecular weight of ~4,921 Da (≈5 kDa) — which sits right at the upper edge of what nasal mucosa can passively absorb. Typical reliable nasal-bioavailability cutoff for unmodified peptides is ~5 kDa or smaller, and even there absorption is poor for systemic effect. What this means in practice: products marketed as “TB-500 nasal spray” using the full-length molecule are very likely under-delivering. The peptide reaches the mucosa but most of it never crosses into the bloodstream. The honest read: if you want systemic effects from TB-500, subcutaneous injection (or IM) is the route that actually works. Topical applications for direct local-tissue effects are reasonable; nasal full-length TB-500 is not. One nuance worth flagging: some products labeled “TB-500 nasal spray” actually contain a much smaller fragment (commonly the LKKTET active sequence, roughly 800 Da), which can absorb nasally — but that’s a different molecule from full-length TB-500 and may produce a different effect profile. Read the product label carefully.
What should I avoid combining — and what's synergistic?
A third, increasingly-cited convention is stacked daily dosing inside the Wolverine pairing: 300–500 mcg of TB-500 alongside 300–500 mcg of BPC-157, daily, often mixed in one vial. When TB-500 is run solo on the loading pattern, the common shorthand is 2–5 mg twice weekly with 1–2-week breaks between cycles. Note one onset detail worth setting expectations for: some users report mild flu-like symptoms or transient lethargy in the first week of TB-500 — early-onset and self-limiting, not a sign the peptide isn’t working.
Stacking. TB-500 + BPC-157 is the classic Wolverine stack (Wolverine (BPC-157 + TB-500)) — systemic migration/repair (TB-500) plus local angiogenesis and FAK-paxillin healing (BPC-157). Add GHK-Cu for GLOW (collagen/skin layer) or KPV for KLOW (immune/anti-inflammatory layer). Some users keep the peptides in separate vials over a denaturing-on-mixing concern; co-dosing from separate syringes sidesteps it.
How can I buy this?
Alyve sells TB-500 as a lyophilized research powder, 10 mg at $59 (a 5 mg variant is currently out of stock). The 10 mg lot (TBS339) carries a third-party Certificate of Analysis from Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity): 99.06% purity, identity confirmed as Thymosin Beta-4.
That identity confirmation matters more for TB-500 than almost anything, precisely because of the fragment-vs-full-Tβ4 and content-variability issues above. The gray market is rough — independent testing has found roughly 1 in 4 research peptides underdosed, mislabeled, or contaminated (often with leftover TFA salt), frequently with no COA. A large 2026 gray-market purity analysis (Mendias et al., preprint — 6,441 samples across 14 compounds, TB-500 among them) puts hard numbers under that variability. A verified >99%-pure, LC-MS-identity-confirmed product is the clean tier, and the lab report is the proof that what’s in the vial is actually Thymosin Beta-4.
Use code OHM-15 for 15% off: Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. TB-500’s loading-then-maintenance dosing burns through product over a cycle, so a 3-bottle order (or a Wolverine-stack bundle with BPC-157) is how committed users buy.
TB-500 is also available from US Pure Peptides — use code OHM20 for 20% off. US-manufactured, ISO 17025-accredited third-party COA testing on every batch, free bacteriostatic water included.
TB-500 is also available from BioLongevity Labs — use code OHM-15 at BioLongevity for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
| Class | Synthetic peptide, a fragment of the natural 43-amino-acid protein thymosin beta-4 (Tβ4) |
| Mechanism (one line) | Sequesters actin to drive cell migration, plus angiogenesis and anti-inflammatory/anti-fibrotic signaling — the systemic “repair coordinator” |
| Route / frequency | Subcutaneous / intramuscular; often a loading phase then maintenance |
| Half-life | Longer-acting than BPC-157 (why it’s dosed less frequently); precise human PK for the fragment |
| Evidence base | Deep, mechanistically coherent animal/in-vitro record; human data exists for clinical-grade Tβ4 (eye drops, wound, cardiac) |
| Safety record | Well-tolerated in available studies; no serious toxicity signal; mild injection-site reactions most common |
| Regulatory status | Not FDA-approved; WADA-banned; a major doping agent in horse racing |
| Alyve product | TB-500 10 mg ($59) · COA 99.06%, identity confirmed Thymosin Beta-4 (lot TBS339) · OHM-15 |
| Best-fit user | Systemic recovery support, often stacked with BPC-157 (the “Wolverine” pairing) |
What it is
TB-500 is the systemic half of the recovery toolkit — where BPC-157 acts locally and fast, TB-500 is the body-wide “repair coordinator.” It’s a synthetic fragment of thymosin beta-4 (Tβ4), a natural protein your cells use to manage their internal scaffolding (actin) and to orchestrate the cell movement that wound healing depends on. People use it for whole-body recovery, soft-tissue repair, and flexibility, most often paired with BPC-157 in the “Wolverine” stack.
Tβ4 was first isolated in 1981 by Dr. Allan Goldstein at the National Institutes of Health from calf thymus tissue — and it turned out to be one of the most abundant proteins inside human cells, found at elevated concentration wherever the body is actively healing (wound sites, torn tendons, damaged muscle). That observation — Tβ4 piling up at injury sites — is what kicked off four decades of research asking whether the protein causes repair or just shows up because of it. The mechanism work below is what answered that question.
The framing worth keeping: TB-500 is a repair accelerant layered on top of the inputs that actually rebuild tissue — sleep, protein, loading, recovery. On that foundation, the biology is genuinely interesting and the preclinical record is broad. The rest of this article walks the mechanism, what the research shows at each tier (including an honest note on which molecule the human trials used), the protocol people run, and the open questions.
How it works
Actin sequestration: the core, best-understood mechanism. Tβ4 grabs free actin monomers (the building blocks of the cell’s internal skeleton) and releases them on demand [PMID 12852258, 17468232]. That control over the cytoskeleton is what lets cells crawl — and migration is the heart of repair: cells have to move into damaged tissue before they can rebuild it. This is also why TB-500 pairs naturally with BPC-157, which drives the local angiogenesis the migrating cells need.
Angiogenesis. Tβ4 promotes new blood vessel formation, increasing perfusion to repairing tissue [PMID 22074294, 27450736].
Anti-inflammatory + anti-fibrotic signaling. Tβ4 down-regulates inflammatory chemokines/cytokines (via NF-κB suppression), reduces TGF-β-driven fibrosis, inhibits the fibroblast-to-myofibroblast conversion that creates scar, and lowers macrophage infiltration [PMID 36580759]. Much of the anti-fibrotic punch may live in a small N-terminal metabolite, ac-SDKP, which has reduced (and in some models reversed) fibrosis in liver, lung, heart, and kidney. This anti-scar-tissue property is part of why TB-500 is emphasized for post-surgical recovery specifically — excess scar formation is a major recovery complication, and TB-500’s profile pushes toward organized repair over fibrosis.
Stem/progenitor activation + cell survival. Tβ4 mobilizes and matures stem/progenitor cells and protects cells from apoptosis [PMID 22074294].
A transparency note on the molecule — and a real labeling trap. Historically “TB-500” meant a shorter synthetic fragment (the active LKKTETQ region) of full Tβ4, and a portion of the active wound-healing biology may reside in specific metabolites. But the term is used inconsistently across vendors: some clinics still use “TB-500” to mean the 7-amino-acid fragment, while higher-tier product (including Alyve’s) is the full 43-amino-acid acetylated thymosin beta-4 sequence — the actual parent molecule the published research is on. Practical takeaway: when you see a study, check whether it used full/recombinant Tβ4 or the fragment — they overlap heavily in mechanism but aren’t identical — and when you buy, confirm which molecule the vial actually contains. That’s a reason to read both the evidence and the COA carefully, not a reason to discount the peptide.
What the research shows
Animal / preclinical: first-class evidence, and this is the bulk of the picture. The preclinical record is mechanistically coherent and spans many organ systems. Strongest first:
- Cardiac repair across models [PMID 27450736, 36709593] — Tβ4 reduces infarct volume, preserves cardiac function, increases vessel growth, and reduces fibrosis after ischemic injury; in adult mouse explants it reactivated epicardial progenitor cells toward vasculature [PMID 17495252].
- Anti-fibrotic switch [PMID 36580759] — benefit in liver, lung, heart, and kidney fibrosis models, with ac-SDKP carrying much of the activity.
- Dermal / wound healing [PMID 20536453, 40279568] — faster dermal healing including in diabetic and aged animals and burns.
- NAFLD inflammation [PMID 40322536] — Tβ4 promoted protective M2 macrophage polarization and reduced liver inflammation; knockdown worsened steatosis.
- Kidney injury [PMID 27575556] — endogenous Tβ4 acts as a brake on glomerular injury; its loss accelerated inflammation and fibrosis.
- Neuro / anti-inflammatory mechanisms [PMID 31612500, 36834849] — TLR/NF-κB modulation, NLRP3 inflammasome suppression, autophagy induction.
Human evidence: exists, for clinical-grade Tβ4, and it’s mixed-but-real. This is the honest part most sources gloss:
- rhTB4 in STEMI heart attack (RCT, n=96, 2025) [PMID 41229390]: pharmaceutical recombinant human Tβ4 after stenting. The overall infarct-area difference vs placebo was not statistically significant, though an early-dosing subgroup (n=43) did show reduced infarct area. The authors call for larger trials. Honest read: a near-miss with a promising signal, not a slam-dunk and not a failure.
- Tβ4 eye drops (RGN-259), dry eye + neurotrophic keratopathy [PMID 30063853] — Phase 2 showed meaningful symptom/sign improvement; Phase 3 trials advanced. Well-tolerated.
- Dermal-wound Phase 2 (pressure/stasis ulcers, epidermolysis bullosa) [PMID 27450738] — accelerated repair, reported safe and well tolerated (disaggregated stats not in the review).
These human trials used clinical-grade Tβ4, not the gray-market TB-500 fragment — an important distinction for honesty. The fragment’s musculoskeletal/sports-recovery uses are supported by mechanism and user experience, not by a dedicated human RCT yet.
Where the evidence is genuinely contested: shown honestly: a 2012 knockout study found Tβ4 is dispensable for normal mouse cardiac development and function [PMID 22158707], which challenges the strongest “Tβ4 is an essential regenerator” developmental claims (the authors suggest earlier shRNA-knockdown studies may have had off-target effects). This doesn’t negate the therapeutic (added exogenous Tβ4) findings — a molecule can be dispensable at baseline yet beneficial when supplied at injury — but it’s a real nuance that tempers the most sweeping regeneration framing. Expert reads differ accordingly: the regenerative-medicine groups (Goldstein/Kleinman/Sosne lineage) treat the repair biology as well-established, while more conservative clinicians note that the strongest human signals are in eye and wound indications, not the recovery use TB-500 is sold for. Both are looking at the same data; the gap is how far they extrapolate to the injectable fragment.
Cardiac applications — mechanism cascade, AFib, and human evidence
This section addresses TB-500’s most significant under-covered application: cardiac repair and regeneration. The animal evidence for cardiac benefit is already in the research section above (PMIDs 27450736, 36709593, 22074294, 36580759). What’s less documented in the OHM wiki — and what makes the cardiac use case compelling — is the step-by-step mechanism cascade, the AFib-specific application, and two named human trials that represent the most important verification targets in the TB-500 body of evidence.
The cardiac mechanism cascade (what TB-500 actually does in damaged heart tissue)
TB-500 operates through a staged cascade in cardiac tissue:
- G-actin pathway activation → bone marrow signaling. TB-500 crosses cell membranes via the same actin-sequestration mechanism that underlies its other tissue-repair effects, and signals the bone marrow.
- Progenitor cell mobilization. Bone marrow-derived progenitor cells are recruited into circulation — the same mechanism as the “stem cell mobilization” aspect of its broader repair biology (PMID 22074294).
- Migration to damaged myocardium. Progenitor cells home to areas of myocardial damage, driven by the tissue-injury signaling gradient.
- Angiogenesis at the site. Progenitor cells release VEGF and FGF → new capillary growth. Previously ischemic tissue gets its first blood supply. Hypoxia resolves. Capillary density +2.1x.
- Anti-fibrotic action. TB-500 downregulates TGF-β signaling → collagen synthesis decreases → fibroblasts stop laying down excess scar tissue → existing fibrotic tissue begins remodeling. Myocardial fibrosis -47% (monotherapy).
- Cardiomyocyte preservation. AKT/mTOR signaling activated in remaining cardiomyocytes → apoptosis suppressed → autophagy upregulated → functional cardiac muscle preserved and strengthened. Cardiomyocyte survival +58%.
- Contractile function recovery. As new vessels integrate, scar tissue is resorbed, and surviving cardiomyocytes adapt, ejection fraction improves and chamber size normalizes. EF recovery: +26% in animal models; +18% in the Renoult 2005 human trial.
The mechanism through steps 1–4 is consistent with the established TB-500 biology already in this article. Steps 5–7 are anchored by the anti-fibrotic and progenitor-cell work (PMIDs 36580759, 22074294). The specific percentages cited above are from the practitioner literature and are on the verification queue.
AFib — a structural problem, not purely an electrical one
The conventional AFib model centers on aberrant electrical signals and re-entrant circuits: rate control, anticoagulation, ablation, pacemaker. A parallel model — consistent with the broader atrial-remodeling literature in cardiology — frames atrial fibrosis as the substrate:
- Chronic systemic inflammation → atrial fibrosis (structural scarring of atrial walls)
- Fibrotic tissue blocks normal electrical conduction pathways and creates zones of slow or blocked conduction
- Re-entrant circuits emerge in the scarred tissue → AFib as a consequence
The important implication: if atrial fibrosis drives aberrant conduction, and TB-500 reverses fibrosis, then TB-500 addresses the structural cause of the arrhythmia — not just the rhythm itself.
Mechanism-specific data for AFib ``:
- Atrial fibrosis -54%
- Spontaneous AFib episodes -73%
- 5 of 7 patients converted to normal sinus rhythm (maintained)
These figures come from the Osma 2003 case series (see below). The atrial-remodeling / fibrosis-as-AFib-substrate framing is independently supported in mainstream cardiology literature (atrial remodeling is well-documented as a perpetuating factor in persistent AFib). The extent to which TB-500 can reverse established atrial fibrosis in humans is what the Osma data answers — if it verifies.
Two named human trials — the priority verification targets
The existing wiki notes the rhTB4 STEMI RCT (PMID 41229390, 2025) as the most relevant current human trial, which was a near-miss (overall result not significant, though an early-dosing subgroup showed reduced infarct area). Two older human trials, cited by the practitioner community, potentially provide stronger direct evidence. Neither has been -confirmed in this OHM pass — they are the highest-priority verification targets for the next research session.
Trial 1 — Renoult 2005, Circulation
- Journal: Circulation (one of the highest-impact cardiovascular journals)
- N = 30 patients (post-MI / significant cardiac dysfunction)
- Duration: 12 weeks of TB-500
- Attributed results: ejection fraction improved, scar tissue reversed, benefits maintained at 3-year follow-up, zero adverse events
- Significance if verified: a 21-year-old human trial for TB-500 cardiac repair in the top cardiology journal, with 3-year durability data. Would be the single strongest human evidence point in the OHM TB-500 article — stronger than the 2025 RCT which was underpowered and delivered a near-miss.
- Search targets: PubMed
"thymosin beta" AND "Circulation" AND 2005 AND "ejection fraction"; also try “Renault” spelling (transcript may have misheard the name).
Trial 2 — Osma 2003, European Heart Journal
- Journal: European Heart Journal (top European cardiology journal)
- Study type: case series
- Indication: atrial fibrillation
- Attributed results: atrial fibrosis -54%, spontaneous AFib episodes -73%, 5/7 patients converted to and maintained normal sinus rhythm
- Significance if verified: the human anchor for TB-500’s AFib application.
- Search targets: PubMed
"thymosin beta" AND "atrial fibrillation" AND 2003; also try author “Osma.”
Review — Srivastava 2018, Nature Reviews Cardiology
- Attributed as a comprehensive analysis of TB-500 and cardiac regeneration, with the conclusion that TB-500 “represents a paradigm shift in cardiac therapeutics — for the first time, evidence that chronic myocardial dysfunction can be reversed through tissue regeneration rather than managed through pharmacological suppression.”
- Search: PubMed
"thymosin beta 4" AND "Nature Reviews Cardiology" AND 2018 AND Srivastava.
The combination protocol (KPV + TB-500) for cardiac restoration
When paired with KPV, the combination addresses both legs of cardiac disease simultaneously: KPV resolves ongoing inflammation (the upstream driver), TB-500 repairs the existing structural damage (the downstream consequence). The synergy is more than additive because both processes run in parallel — inflammation control enables more effective tissue regeneration, and tissue regeneration reduces the inflammatory burden.
Combination outcome data:
| Endpoint | Δ at 12 weeks |
|---|---|
| Ejection fraction | +34% |
| LVEDD (chamber size) | -24% |
| Myocardial fibrosis | -63% |
| Major Adverse Cardiac Events (MACE) | -61% |
If a primary source exists for these numbers, it belongs here with full citation. Until then, cite as practitioner-reported combination outcomes.
The staged combination protocol:
Protocol context: this is what a practitioner in the peptide-education space publishes for serious cardiac patients. OHM presents it for educational framing. Anyone with an active cardiac diagnosis should work with a qualified physician; peptides should not replace prescribed cardiac medications without medical supervision.
| Phase | Duration | KPV | TB-500 | Goal |
|---|---|---|---|---|
| 1 — Inflammation control | Weeks 1–4 | 500 mcg/day, divided (250 mcg twice daily) | None | Reduce systemic inflammation, stabilize plaques, restore endothelial function |
| 2 — Begin regeneration | Weeks 4–5 | Continue | 2.5 mg IM twice weekly | Activate progenitor cell mobilization, angiogenesis, anti-fibrotic action |
| 3 — Sustained regen | Months 2–7 | Continue divided dose | 2.5 mg IM weekly | Complete cardiac repair cycle |
Note on route — IM for cardiac use: the standard OHM TB-500 route is SubQ. One practitioner specifies IM (intramuscular) for the cardiac indication specifically, though without elaborating the pharmacokinetic rationale in this video. The likely reasoning: IM provides faster peak plasma concentration when the therapeutic target is myocardial tissue at distance from a subcutaneous depot. This is the one context where IM is explicitly flagged over SubQ.
Note on cycling: standard cycling discipline (on/off cycles) does not apply in the cardiac-repair context, per this framing. When the goal is tissue regeneration for an active cardiac condition, continuous use through the repair trajectory is the appropriate posture. Cycling is a fitness-enhancement convention; cardiac repair is a therapeutic priority.
Cardiac monitoring protocol:
- Echocardiogram: baseline, week 12, week 24 — tracks EF, chamber dimensions, wall motion
- ECG: baseline, week 24 (especially for AFib patients) — tracks rhythm normalization
- Inflammatory markers (CRP, TNF-alpha, IL-6): baseline, week 12, week 24
- Functional capacity testing: baseline, midpoint, week 24
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
Reconstitution (objective math). A 10 mg vial reconstituted with 2 mL bacteriostatic water gives 5 mg/mL (5,000 mcg/mL). On a U-100 insulin syringe, a 500 mcg dose = 0.1 mL = 10 units. Add water slowly down the vial wall, swirl gently, never shake; refrigerate reconstituted.
Two common dosing conventions: and they differ, which is worth knowing:
- Cheat-sheet / clinic convention (one practitioner): 10 mg vial in 2 mL, 500 mcg dosed AM, daily, 8 weeks on / off.
- Forum loading protocol: a loading phase of 2–5 mg twice weekly for the first 4–6 weeks, then a lower-frequency maintenance dose (e.g., 2–5 mg once weekly or every other week). This is a much higher per-injection amount than the cheat-sheet’s daily 500 mcg.
The two reflect different philosophies — daily microgram dosing vs. front-loaded milligram dosing leaning on Tβ4’s longer half-life. Both are in real-world use; the loading-then-maintenance pattern is the more commonly cited approach for TB-500 specifically, because the molecule lasts longer than BPC-157 and doesn’t need daily injections. There’s no human dose-finding trial for the fragment to anchor either, so these are community-converged protocols, stated plainly as such.
A third, increasingly-cited convention is stacked daily dosing inside the Wolverine pairing: 300–500 mcg of TB-500 alongside 300–500 mcg of BPC-157, daily, often mixed in one vial. When TB-500 is run solo on the loading pattern, the common shorthand is 2–5 mg twice weekly with 1–2-week breaks between cycles. Note one onset detail worth setting expectations for: some users report mild flu-like symptoms or transient lethargy in the first week of TB-500 — early-onset and self-limiting, not a sign the peptide isn’t working.
Stacking. TB-500 + BPC-157 is the classic Wolverine stack (Wolverine (BPC-157 + TB-500)) — systemic migration/repair (TB-500) plus local angiogenesis and FAK-paxillin healing (BPC-157). Add GHK-Cu for GLOW (collagen/skin layer) or KPV for KLOW (immune/anti-inflammatory layer). Some users keep the peptides in separate vials over a denaturing-on-mixing concern; co-dosing from separate syringes sidesteps it.
Route considerations — why nasal spray is the wrong format for full-length TB-500. ✅ Verified 2026-06-20. Full-length TB-500 (Thymosin Beta-4) is a 43-amino-acid polypeptide with a molecular weight of ~4,921 Da (≈5 kDa) — which sits right at the upper edge of what nasal mucosa can passively absorb. Typical reliable nasal-bioavailability cutoff for unmodified peptides is ~5 kDa or smaller, and even there absorption is poor for systemic effect. What this means in practice: products marketed as “TB-500 nasal spray” using the full-length molecule are very likely under-delivering. The peptide reaches the mucosa but most of it never crosses into the bloodstream. The honest read: if you want systemic effects from TB-500, subcutaneous injection (or IM) is the route that actually works. Topical applications for direct local-tissue effects are reasonable; nasal full-length TB-500 is not. One nuance worth flagging: some products labeled “TB-500 nasal spray” actually contain a much smaller fragment (commonly the LKKTET active sequence, roughly 800 Da), which can absorb nasally — but that’s a different molecule from full-length TB-500 and may produce a different effect profile. Read the product label carefully.
Side effects & management
TB-500 is well-tolerated in the available data, with no serious toxicity signal.
- Injection-site reactions (redness, swelling, irritation) — most common; rotate sites, clean technique.
- Mild headache or transient lethargy — occasionally reported.
- No detectable effect in a minority of users — sometimes a product-quality issue (the gray-market fragment’s actual content varies, which is exactly what a COA solves).
- Cancer caution — the same angiogenesis/cell-migration biology that drives repair overlaps mechanistically with tumor biology, so suspected or active malignancy is a sensible contraindication to discuss with an oncologist. This is mechanism-based caution, not documented human harm — and note the anti-fibrotic/anti-inflammatory arms of Tβ4 cut the other way. Pregnancy is also commonly listed as a contraindication.
The largest real-world variable isn’t the side-effect profile — it’s whether the vial contains correctly-dosed, identity-confirmed TB-500 in the first place, which is the supply-chain point below.
Use in dogs and cats (vet practice)
TB-500 has the longest-running vet practitioner adoption pattern of any peptide in the OHM catalog — its horse and racehorse medicine use case established the equine veterinary precedent long before companion-animal use caught up. The mechanism (endothelial cell migration, vascular regeneration, tissue repair) is conserved across mammals; the foundational research was largely animal. In companion-animal practice, TB-500 is used for post-injury and post-surgical recovery, joint and ligament rehab in active or working dogs, slow-healing wounds, and senior-pet recovery support. The “Wolverine” pairing with BPC-157 (covered in Wolverine (BPC-157 + TB-500)) is the canonical regenerative-medicine stack for vet rehab — TB-500’s vascular regeneration + BPC-157’s growth-factor-receptor-modulating tissue repair cover complementary repair mechanisms. Practitioner-camp dosing is weight-dosed; work with a vet familiar with peptide therapy. TB-500 carries the same theoretical “supports growth signaling” caution around active malignancy that applies on the human side — screen for pre-existing cancer before starting in senior pets. See Peptides for Pets for the broader companion-animal framework.
Regulatory status
Not FDA-approved for any use. Prohibited by WADA and a well-known doping agent in horse racing (its cytoskeletal/cell-movement effects). The FDA reopened consideration of peptide-compounding policy in 2026, but no approval exists for TB-500. Sold legally as a research chemical, “not for human consumption.” Note that the clinical-grade Tβ4 programs (RGN-259, rhTB4) are separate regulated drug-development efforts and don’t confer approval on the gray-market fragment.
Worth noting the signal value of the equine ban specifically: published methods exist for detecting TB-500 in horse urine and plasma — people watching elite-racehorse injury-recovery timelines (with millions of dollars on the line) decided this molecule warranted a dedicated detection protocol. That’s not proof of human athletic-recovery efficacy, but it is a meaningful inference about what the people closest to high-value soft-tissue injuries believe.
The Alyve product
Alyve sells TB-500 as a lyophilized research powder, 10 mg at $59 (a 5 mg variant is currently out of stock). The 10 mg lot (TBS339) carries a third-party Certificate of Analysis from Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity): 99.06% purity, identity confirmed as Thymosin Beta-4.
That identity confirmation matters more for TB-500 than almost anything, precisely because of the fragment-vs-full-Tβ4 and content-variability issues above. The gray market is rough — independent testing has found roughly 1 in 4 research peptides underdosed, mislabeled, or contaminated (often with leftover TFA salt), frequently with no COA. A large 2026 gray-market purity analysis (Mendias et al., preprint — 6,441 samples across 14 compounds, TB-500 among them) puts hard numbers under that variability. A verified >99%-pure, LC-MS-identity-confirmed product is the clean tier, and the lab report is the proof that what’s in the vial is actually Thymosin Beta-4.
Use code OHM-15 for 15% off: Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. TB-500’s loading-then-maintenance dosing burns through product over a cycle, so a 3-bottle order (or a Wolverine-stack bundle with BPC-157) is how committed users buy.
Technical & analytical reference (chemistry & QC)
Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited. Two distinct molecules are listed because vendors conflate them: “TB-500” as sold is usually the short synthetic Tβ4 fragment (17-23), NOT the full 43-mer Thymosin β-4. Check which one any given study or vial actually refers to.
| Field | TB-500 (Tβ4 fragment 17-23) | Full Thymosin β-4 (parent 43-mer) |
|---|---|---|
| Molecular formula | C39H67N9O13 | C212H350N56O78S (PubChem CID 16132341) |
| Average MW | 877.99 g/mol | ~4963.4 g/mol |
| CAS | 885340-08-9 | 77591-33-4 |
| Sequence | Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ) | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES |
| Analytical field | Value |
|---|---|
| HPLC purity criterion | RP-HPLC (C18, acetonitrile/water + 0.1% TFA), detection 214 nm; ≥95% research-grade, <2% total impurities |
| MS identity | Fragment: ESI-MS (M+H)+ ≈ m/z 878.0 ± 1 Da. Full Tβ4: MALDI/ESI-MS ~4963.4 Da |
| Counterion / net peptide | Acetate or HCl salt; AAA peptide content typically ~70–85% by weight (remainder counterions, moisture, residual solvent) |
| Storage / reconstitution | Lyophilized −20°C (24–36 mo) / 2–8°C (12–18 mo); reconstitute slowly down vial wall, swirl (never shake); reconstituted 2–8°C ~14–28 days |
| Degradation / stability | Max stability pH ~4.0–6.0; primary pathways = Asn/Gln deamidation (faster at pH 7.4), Met oxidation, Asp-Pro hydrolysis, aggregation |
| Reported PK (fragment, rodent) | SC Cmax ~200–400 ng/mL at 0.5–1 h (6 mg/kg); elimination t½ ~1.5–3 h; SC bioavailability ~60–80% vs IV |
Primary-literature citation leads (PeptideBiologix; confirm before citing): PMID 6940067 (Low 1981, full Tβ4 sequence), PMID 1374908 (Sanders 1992, actin sequestration), PMID 14517432 (Grant 1999, angiogenesis), PMID 15565145 (Bock-Marquette 2004, cardiac repair), PMID 17108969 (Smart 2007, epicardial progenitors), PMID 12581422 (Philp 2003, dermal wound repair), PMID 18427126 (Hinkel 2008, porcine MI), PMID 20627173 (Morris 2010, stroke), PMID 17254567 (Sosne 2007, corneal NF-κB).
Sources
- PMIDs 41229390, 22158707, 30063853, 27450738, 27450736, 22074294, 36580759, 12852258, 17468232, 17495252, 40322536, 27575556, 36709593, 31612500, 36834849, 40279568.
- Innerbody, The Conversation (McGuire MD), Jeffrey Peng MD, Prisk MD.
- (lot TBS339).
- Mendias 2026 gray-market peptide-purity preprint (TB-500 included in the 6,441-sample analysis).
- Video digests: Huberman/Bakri peptides (2026-06-01, TB-500 / Wolverine sections); Holyfield Wolverine personal case studies (2026-06-08, stacked dosing / flu-like onset / anti-scar emphasis); Durst/Golombiewski BPC-157+TB-500 healing clinic protocol (2026-06-08, clinic-default combo + TB-4/TB-500 nomenclature); Sean PeptideAtoZ “Why Was TB-500 Banned?” (2026-06-16, ): adds the Goldstein-1981-NIH discovery story, the “cellular logistics peptide” repositioning handle, and the racehorse-detection-protocol signal-value reframe; one practitioner “KPV and TB500N vs Cholesterol, AFib and Heart Disease” (2026-07-11, ): the cardiac applications section (mechanism cascade, AFib structural model, Renoult 2005 and Osma 2003 human trial citations, combination protocol, IM route specification for cardiac use, monitoring protocol).
Related: BPC-157 · Wolverine (BPC-157 + TB-500) · GLOW · KLOW.
Sources & references
- PMIDs 41229390, 22158707, 30063853, 27450738, 27450736, 22074294, 36580759, 12852258, 17468232, 17495252, 40322536, 27575556, 36709593, 31612500, 36834849, 40279568.
- Innerbody, The Conversation (McGuire MD), Jeffrey Peng MD, Prisk MD.
- (lot TBS339).
- Mendias 2026 gray-market peptide-purity preprint (TB-500 included in the 6,441-sample analysis).
- Video digests: Huberman/Bakri peptides (2026-06-01, TB-500 / Wolverine sections); Holyfield Wolverine personal case studies (2026-06-08, stacked dosing / flu-like onset / anti-scar emphasis); Durst/Golombiewski BPC-157+TB-500 healing clinic protocol (2026-06-08, clinic-default combo + TB-4/TB-500 nomenclature); Sean PeptideAtoZ “Why Was TB-500 Banned?” (2026-06-16, ): adds the Goldstein-1981-NIH discovery story, the “cellular logistics peptide” repositioning handle, and the racehorse-detection-protocol signal-value reframe; one practitioner “KPV and TB500N vs Cholesterol, AFib and Heart Disease” (2026-07-11, ): the cardiac applications section (mechanism cascade, AFib structural model, Renoult 2005 and Osma 2003 human trial citations, combination protocol, IM route specification for cardiac use, monitoring protocol).
Related: BPC-157 · Wolverine (BPC-157 + TB-500) · GLOW · KLOW.
Community experience reports
Anecdotal — real-world reports from the peptide community, not clinical evidence. Presented alongside the graded science above, not as a substitute for it.
Companion raw digest: Evidence tier: throughout Last updated: 2026-07-10 Cross-refs:
[BPC-157](/peptides/bpc-157/)·*wolverine-blend*·*glow-blend*·*klow-blend*
Who reports the strongest results
One category dominates: people with chronic, treatment-resistant soft-tissue injuries. Rotator cuffs, Achilles tendons, patellar tendons, bicep tears, muscle tears, plantar fascia — injuries that haven’t responded to physical therapy, PRP, corticosteroids, or rest. TB-500’s community reputation is built on doing what conventional treatment couldn’t: driving structural repair in tissue that had stopped healing.
The pattern that repeats: “I’d had this [shoulder / knee / Achilles] injury for [6 months / 2 years / 7 years], tried everything, and TB-500 was what finally moved it.”
What the community actually says
Healing vs pain relief — the distinction that matters
Users don’t describe pain relief. They describe healing. The community-level distinction is explicit and important: TB-500 is not an analgesic. The mechanism described is actual tissue remodeling over weeks.
- Pain reduction typically noticeable by weeks 1–2
- Functional return (strength, range of motion) comes later — weeks 4–6 during loading
- Consistent community warning: “Pain drops faster than structural integrity returns — don’t rush back to full training” — this exact framing appears across threads from multiple communities and injury types
Less conventional applications that appear consistently
Two applications recur often enough across forums to note:
- Eye floater reduction — partial resolution documented across multiple user accounts; mechanism proposed as angiogenesis improving ocular vasculature; unconfirmed
- Chronic fissure healing — at least one detailed log documents healing a chronic anal fissure unresponsive to standard treatment
Protocol as used by the community
Loading phase: 2–2.5 mg SubQ or IM, twice per week, for 4–6 weeks
Maintenance phase: 1–2 mg per week for 4–8 additional weeks
Half-life estimate: Community pegs this at 5–7 days — drives the twice-weekly loading frequency to maintain tissue saturation during acute healing.
Injection approach — the local vs systemic debate: Community is divided but not strongly. Systemic SubQ injection (abdomen) is more common for convenience and diffuse injuries. Some users inject near the injury site for concentrated local effect. No clear consensus on superiority. For multiple or hard-to-pinpoint injuries, systemic is recommended.
Pairing with BPC-157 (the Wolverine stack):
TB-500 and BPC-157 are viewed as complementary — TB-500 for systemic/diffuse soft-tissue repair and muscle; BPC-157 for tendons, nerves, and gut with stronger local injection data. Together they cover more ground than either alone. See *wolverine-blend*.
Side effects and risk signals
Side effect profile is generally mild.
- Lethargy early in cycles (resolves within 1–2 weeks)
- Headache occasional; dose-dependent
- Temporary pain flare at injury site first 1–2 weeks — experienced users interpret as biological activity, not damage
- Injection site redness and mild swelling (standard peptide injection)
Cancer / angiogenesis concern (theoretical): TB-500 promotes angiogenesis (new blood vessel formation). Theoretical concern: could also support growth of pre-existing tumors. No confirmed cases in community use; the mechanism is real but the risk to healthy users is unquantified. Community consensus is clear: not appropriate for anyone with known or suspected malignancy. Flag this for users who raise the question.
WADA S0 ban: Prohibited for tested athletes. Non-tested users are unaffected by this classification.
Non-response: ~40% and why
About 40% of users report no meaningful effect. In order of how often each cause is cited:
- Product quality — the most common attributed cause; purity and actual peptide content vary enormously across suppliers
- Underdosing during loading — the 2–2.5 mg twice-weekly loading dose matters; cutting it to save cost correlates with non-response
- Wrong injury type — TB-500 is a soft-tissue peptide; expectations of bone repair or purely articular cartilage healing are frequently disappointed
- Stopping too early — some users quit before completing the 4–6 week loading phase
Frequently asked questions (community version)
TB-500 vs BPC-157 — which for which injury? Community rules of thumb: BPC-157 for gut issues, nerve damage, tendons with local injection; TB-500 for diffuse/systemic soft tissue, muscle tears, cardiorespiratory function. Wolverine stack (both) is the community gold standard for serious musculoskeletal injuries.
Does the WADA ban affect me? Only if you compete in a WADA-tested sport. For recreational users and non-tested athletes, the classification has no practical effect on legality or use.
Is the cancer concern real? The angiogenic mechanism is real. The risk to otherwise healthy people is theoretical and unquantified in practice. Community consensus: acknowledged as a legitimate signal; not seen as prohibitive for healthy users; an absolute contraindication for anyone with known or suspected malignancy.
Where should I inject — near the injury or systemically? Both approaches report success. For a defined single-site injury, some prefer local injection. For diffuse injuries or multiple sites, systemic SubQ is simpler and reportedly effective. No strong evidence base for either being universally superior.
Notable community accounts
- cdoubleu (MESO-Rx): 7-year chronic shoulder injury unresponsive to PT and PRP; 6-week loading protocol; pain substantially reduced by week 4; returned to weight training by week 8
- Gigantic (forum): Chronic anal fissure resolved after SubQ TB-500 loading — documented as example of systemic reach beyond musculoskeletal application
- Rokslide hunting/athletics community: Multiple accounts of knee, shoulder, and Achilles recovery enabling return to hunting and climbing after a year+ of failed conventional treatment
Cross-references
[BPC-157](/peptides/bpc-157/)— most natural pairing; the other half of the Wolverine stack*wolverine-blend*— BPC-157 + TB-500 combination community reports*glow-blend*— Wolverine + GHK-Cu (adds cosmetic/skin layer)*klow-blend*— Wolverine + GHK-Cu + KPV (full recovery + gut + inflammation)
Commercial note
TB-500 is available through Alyve — use code OHM-15 at checkout for 15% off.